Background: Little is known about the effect of provider continuity prior to the diagnosis of advanced lung cancer and endof-life care.
Introduction
Outpatient provider continuity is central to the ''medical home'' concept of the Patient Protection and Affordable Care Act and is key to good medical care [1] . It is associated with improved patient satisfaction, [2] increased use of appropriate preventive health services [3] [4] [5] [6] [7] , greater medication compliance, lower hospitalization rates, [8] [9] [10] [11] [12] less emergency department use [13] and fewer duplicate tests. [14] Moreover, continuity of care with a primary care physician (PCP) has shown substantial reductions in mortality among older adults. [15] Continuity is beneficial for cancer patients both prior to and after diagnosis. Pre-diagnosis continuity leads to diagnoses at earlier stages. [16] PCP continuity after cancer diagnosis increases the likelihood of receiving guideline concordant therapy, [17] decreases the likelihood of emergency room visits in the last six months of life, [18] and increases the likelihood of dying at home. [19] Patients visited by their PCP during their last hospitalization (outpatient to inpatient provider continuity) are less likely to receive Intensive Care Unit (ICU) care. [20] Studies of the effects of continuity on end-of-life care in cancer patients are primarily limited to patients already diagnosed with cancer. We were interested in whether the continuity established prior to this life-and care-altering event (diagnosis of advanced lung cancer) has enduring effects on the end-of-life medical care these patients received. Our hypothesis was that provider continuity prior to the diagnosis of advanced cancer is associated with lower hospitalization, less ICU use, less chemotherapy use and higher hospice use at the end of life. These measures are considered indicators of potentially appropriate care. We used a national sample of newly-diagnosed advanced lung cancer patients to examine the effect of provider continuity prior to the diagnosis of advanced lung cancer on end-of-life medical care.
Methods

Data Source
This is a retrospective study of advanced lung cancer patients identified from the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database for the years 1993-2005. We included the 13 SEER registry geographic regions: the states of Connecticut, Hawaii, Utah, New Mexico, Iowa, California, Kentucky, Louisiana and New Jersey; rural Georgia; and the municipalities of Detroit, MI; Seattle, WA; and Atlanta, GA. For all incident cancers diagnosed in these areas, the SEER registries collect information on patient demographics, tumor characteristics, stage at diagnosis, date of diagnosis, therapy received within four months of diagnosis, and date and cause of death.
Through a collaborative project between the National Cancer Institute and the Centers for Medicare and Medicaid Services (CMS), entitlement information and claims data from the Medicare program were linked to the SEER data for cancer patients aged 65 and older. Medicare eligibility could be identified for 93% of SEER patients aged 65 and older.
Data from multiple files were used for this study: 1) the Patient Entitlement and Diagnosis File (SEER registry data and Medicare entitlement information); 2) Medicare Provider Analysis and Review file (MEDPAR, hospital inpatient and skilled nursing facility stays); 3) Outpatient Standard Analytic File (hospital outpatient services); 4) Physician/Supplier File (physician and other medical services); and 5) Hospice File. To have completeness of information in the Medicare files of these patients, we excluded those enrolled in an HMO at any time from two years before date of diagnosis through date of death.
Study Cohort
Measures
Patient characteristics. Patients' sociodemographic characteristics were obtained from the SEER data and included the following variables: age (67-74, 75-84, $85 years), gender (male, female), race/ethnicity (non-Hispanic white, Black, Hispanic, Other), diagnosis year and SEER geographic region. Socioeconomic status was based on whether the patient was eligible for state buy-in coverage provided by the Medicaid program for at least one month during the year of diagnosis. Comorbidity was measured with the Charlson comorbidity score (0, 1, 2, $3) using all Medicare claims from the year prior to diagnosis. [9] Survival time after diagnosis was measured in months (,1, 2-3, 4-6, 7-12, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . We also included the number of hospitalizations (0, 1, $2) in the 13-24 months before diagnosis as an independent variable.
Definition of study variables. HCFA Common Procedure Terminology (CPT) evaluation and management codes 99201 to 99205 (new patient) and 99221 to 99215 (established patient encounters) were used to establish outpatient visits. Individual providers were determined using the Unique Provider Identification Number (UPIN). We examined visits to PCPs and to any provider. PCPs included those in: family medicine, general practice, internal medicine and geriatrics. For female patients, OB/Gyn was included. Any provider was defined as a primary physician or an internal medicine specialist. To avoid overestimation of visits and continuity, we excluded visits that occurred one month prior to the diagnosis of lung cancer. Visits between months 22 to 213 constitute a year prior to diagnosis (herein referred to as the year prior to diagnosis). In some analyses we assessed visits in months 213 to 224 prior to diagnosis.
Provider continuity. We examined visit patterns for PCPs and for any provider separately as a measure of continuity. Visits to a PCP were defined as the total number of PCP visits in the year prior to diagnosis. (0, 1-3, 4-7, .7). Number of PCPs was defined as the number of unique PCPs seen in the year prior to diagnosis. Having more than one PCP was defined as seeing multiple PCPs.
Visits to any provider was defined as the total number of visits to any physician in the year prior to diagnosis (0, 1-3, 4-7, .7). Number of any providers seen was defined as the number of unique providers seen in the year prior to diagnosis (unique UPINs). Seeing more than one physician was defined as having multiple providers. We assigned a PCP or a provider to a given patient with whom he/she had the majority of outpatient visits in the year prior to diagnosis of advanced lung cancer.
We also used the time exposure method of continuity as defined by Wolinsky et al. [21] To calculate this measure, we expanded the pre-diagnosis period to two years and defined continuity (yes/no) as having visited the same physician twice within any eight months during that time.
Outcomes. Our outcome of interest was medical care during the end of life. We examined hospitalization, ICU use, and chemotherapy use during the last month of life, and hospice use during the last week of life. The first three were considered indicators of potentially aggressive (overtreatment) end of life care and hospice use as appropriate end of life care.
The study was approved by the Institutional Review Board of the University of Texas Medical Branch, Galveston, TX. Deidentified data provided by SEER-Medicare were analyzed and no prior informed consent was required. The manuscript was approved by SEER-Medicare for anonymity prior to submission for publication.
Statistical Analysis. The chi square test was used to compare end-of-life care by patient characteristics. Multivariate logistic regression analyses were used to assess whether different continuity measures affected end-of-life care (yes/no). Both patient characteristics (including age, gender, race, diagnosis year, geographic region, comorbidity, survival time, number of hospitalizations in the 13-24 months before diagnosis) and continuity measures (having a PCP, number of PCPs, total number of visits to PCP, total number of visits to assigned PCP, time exposure method of continuity) were added to the final model. All analyses were performed with SAS version 9.2 (SAS, Inc., Cary, NC). All reported p-values were two-sided and p,0.05 was considered statistically significant. Table 1 presents the baseline characteristics of the cohort and medical care measures (hospitalization during the last month of life, ICU use during the last month of life, chemotherapy use during the last month of life, and hospice use during the last week of life) in 69,427 patients diagnosed with advanced lung cancer who were followed for 24 months. Younger patients, males, nonwhites and those with low socioeconomic status were more likely to be hospitalized and to receive ICU care during the last month of life. Hospice use was more common in females, non-Hispanic whites and those with higher socioeconomic status. Patients with Table 2 presents the bivariate analyses for several measures of provider continuity and end-of-life care. Seeing a PCP in the year prior to a diagnosis of advanced lung cancer increased the likelihood of hospitalization, ICU care during the last month of life, as well as hospice use during the last week of life. The association between end-of-life care and number of PCPs seen and number of outpatient visits to PCPs was inconsistent. Table 3 shows the results of multivariable analyses of the association between provider continuity and end-of-life care measures. Seeing a PCP or any provider and having continuity with a PCP or any provider was associated with increased risk of hospitalization, ICU use and chemotherapy use during the last month of life, as well as hospice use during the last week of life. The odds of hospitalization and ICU use in the last month of life increased stepwise with an increase in number of visits. For example patients with 1-3, 4-7 or .7 visits to their PCP in the year prior to the diagnosis of lung cancer had 1.0 (reference), 1.08 (95% CI; 1.04-1.13), and 1.14 (95% CI; 1.08-1.19) odds of hospitalization during the last month of life, respectively. The results were similar for analyses limited to patients with an identifiable PCP. There was no clear association with hospice use during the last week of life, except for higher odds in patients with outpatient visits to multiple PCPs compared to those whose visits were all to the same PCP. Patients who made more visits ($7) to their assigned PCP had 0.91 (0.86-0.96) lower odds of hospice use during the last week of life. There was no difference in end-of-life care measures using the time exposure method.
Results
One potential confounder in analysis of pre-diagnosis continuity of care with post-diagnosis care is that earlier provider visits, precipitated by symptoms of the yet-undiagnosed cancer, may affect the estimation of true continuity of care. To address that possibility, we repeated all analyses using measures of provider visits generated in the period 13-24 months prior to the diagnosis of advanced lung cancer. Those analyses produced very similar results to those shown for the analysis using the 2-13 months prior to diagnosis.
Discussion
Prior studies on continuity and end-of-life care in patients with cancer have focused on patient-provider patterns following cancer diagnosis. [18-20;22-24] Continuity of care after diagnosis seems to matter. However, whether the continuity established prior to diagnosis of advanced lung cancer has an effect on end-of-life medical care is unknown. We examined associations between several measures of provider continuity prior to the diagnosis and medical care received during end of life.
Provider continuity in the year prior to the diagnosis of advanced lung cancer was not substantially associated with less aggressive medical care during end-of-life care. However, survival time had a significant effect on end-of-life care. Patients with shorter survival were more likely to receive aggressive care whereas those with longer survival were likely to receive hospice care at the end of life. Long term survivors likely represent individuals with lung cancer sensitive to the standard initial chemotherapy and radiotherapy. These individuals are unlikely to benefit from additional treatment later in the course of their disease; thus, they are more likely to opt for hospice care. Moreover, longer survivors also had more time to cope with their terminal illness and perhaps are better prepared for end of life. Hospice care focuses on palliative care and symptom management rather than disease treatment. Our study showed both aggressive and palliative care increased over time, similar to prior reports [20;25] . Patients are choosing both types of care, rather than one or the other, regardless of provider continuity. These results are similar to a Kronman et al. study which showed no clear effect of PCP visits on hospice care. [26] A recent randomized control trial showed that patients with advanced lung cancer who received early palliative care consultation in addition to standard treatment were less likely to receive aggressive care during end of life and lived 2.6 months longer than those who received standard treatment alone [27] . The benefits seen in this study likely arise from better understanding of their disease process and more time to declare their end of life choices.
Our findings are consistent with the study by Kronman et al. of decedent Medicare beneficiaries; compared to patients with no PCP visits during the 7-18 months prior to death, those with $9 PCP visits were hospitalized more frequently (0.9 versus 1.3 admissions), but they averaged 1.9 fewer days in the hospital during the last 6 months of life. [26] We did not examine the total number of days spent in the hospital, but whether patients had any hospital or ICU stay during the last month of life. Inherent to any continuity of care measure, whether based on visit pattern or indices, is the assumption that higher continuity of care leads to greater patient-physician trust. End-of-life decisions are often based on value, preferences and trust between patient and provider. A recent mixed method study of cancer patients showed that ''experiencing continuity'' involves receiving consistent time and attention, knowing future expectations, managing family consequences, coping between service contacts and believing that nothing has been overlooked. [28] Higher ''experienced continuity'' is associated with lower care needs. These aspects of continuity are not captured in claims data.
Our study has several limitations. Information on patient preferences and appropriateness of clinical care is not available in claims data. These findings are limited to fee-for-service Medicare beneficiaries and are not generalizable to other populations. A patient's preferences change following diagnosis of a terminal illness and during the course of his or her disease. Moreover, a recently-diagnosed cancer patient tends to see several new providers in multiple care settings. Our study is limited to advanced lung cancer patients with generally poor survival and the results may not be applicable to patient diagnosed with other cancers. Lack of detailed information on patient's medical and social status in claims data may have added unmeasured confounding and potential explanation for lack of association between prior continuity and end of life care.
In conclusion, our study showed no consistent association between provider continuity prior to diagnosis of advanced lung cancer and end of life care. Continuity did not substantially reduce potentially inappropriate or increase potentially appropriate care during end of life.
